

Lund University was founded in 1666 and is repeatedly ranked among the world's top 100 universities. The University has 42 000 students and 7 400 staff based in Lund, Helsingborg

and Malmö. We are united in our efforts to understand, explain and improve our world and the human condition. The department of Immunotechnology is part of LTH, the Faculty of Engineering at Lund University, with approximately 9 000 students, 900 researchers and 500 PhD students. The research carried out at LTH is of a high international standard.

## Tenure Track Position in Immunotechnology and Antibody engineering

The Department of Immunotechnology are proposing a highly motivated junior researcher, a tenure track position at the Department of Immunotechnology. We offer a unique research environment, aiming for novelty and excellence in the field of immunotechnology. To complement the research at the department we are looking for a researcher, performing independent research in the field of antibody engineering with focus on applications within oncology.

The Department of Immunotechnology, performing world leading research in the field of applied immunology and has a long history of innovation driven research. The main research areas are oncology, allergy, autoimmunity, neurobiology, and antibody engineering. Our research employs advanced technologies including different types of microarray technologies (affinity proteomics), phage display, genomics and transcriptomics, large-scale mass spectrometry-based proteomics, and associated bioinformatics. In addition, we provide genomics and proteomics services, and our antibody development platform has been integrated into SciLifeLab's Drug Discovery and Development Platform. The Department of Immunotechnology, today situated at Medicon Village, has a strong history of entrepreneurship and several companies have derived from the department, e.g. BioInvent, Immunovia, Alligator Bioscience, SenzaGen. The application of advanced technologies to solve complex biomedical challenges has taken the department to the forefront in several research areas.

The position will be part of CREATE Health, a Strategic Centre for Translational Cancer research. The Centre was funded mainly by the Swedish Foundation for Strategic Research, Knut and Alice Wallenberg Foundation and VINNOVA, with the vision to use an integrative approach to develop novel diagnostics and therapeutics. By integrating clinicians and researchers from Lund University Hospital with researchers from the Faculties of Medicine, Natural Sciences and Engineering using a superbly equipped and integrated "omics" platform, concentrated in a single area, a centre unique in its kind was created. This centre has been very successful, eg new diagnostic markers for pancreatic cancer has been disovered and discovery of novel serum-based clinical test for ovarian cancer.